Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jourdan

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
International Journal of Clinical Pharmacy|July 12, 2011
Induction-related cost of patients with acute myeloid leukaemia in FranceVirginie Nerich, Bruno Lioure, Maryline Rave, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2012
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemiaIrene M Ghobrial, Philippe Moreau, Brianna Harris, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 6, 2018
Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric TrialSylvain Carras, Benjamin Dubois, Delphine Senecal, et al.
British Journal of Haematology|July 31, 2021
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosisAnimesh Pardanani, Ayalew Tefferi, Tamás Masszi, et al.
American Journal of Hematology|March 12, 2014
Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNANicolas Duployez, Olivier Nibourel, Alice Marceau-Renaut, et al.
Leukemia Research|December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failureSylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Blood|September 2, 2006
CD200 is a new prognostic factor in multiple myelomaJerome Moreaux, Dirk Hose, Thierry Reme, et al.
NAR Genomics and Bioinformatics|September 25, 2024
Effective requesting method to detect fusion transcripts in chronic myelomonocytic leukemia RNA-seqFlorence Rufflé, Jérôme Reboul, Anthony Boureux, et al.
British Journal of Haematology|April 22, 2005
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remissionEric Jourdan, Françoise Rigal-Huguet, Gerald Marit, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
International Journal of Clinical Pharmacy|July 12, 2011
Induction-related cost of patients with acute myeloid leukaemia in FranceVirginie Nerich, Bruno Lioure, Maryline Rave, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2012
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemiaIrene M Ghobrial, Philippe Moreau, Brianna Harris, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 6, 2018
Interim PET Response-adapted Strategy in Untreated Advanced Stage Hodgkin Lymphoma: Results of GOELAMS LH 2007 Phase 2 Multicentric TrialSylvain Carras, Benjamin Dubois, Delphine Senecal, et al.
British Journal of Haematology|July 31, 2021
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosisAnimesh Pardanani, Ayalew Tefferi, Tamás Masszi, et al.
American Journal of Hematology|March 12, 2014
Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNANicolas Duployez, Olivier Nibourel, Alice Marceau-Renaut, et al.
Leukemia Research|December 3, 2014
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failureSylvain Thepot, Simone Boehrer, Valérie Seegers, et al.
Blood|March 7, 2007
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaKarène Mahtouk, Dirk Hose, Pierre Raynaud, et al.
Blood|September 2, 2006
CD200 is a new prognostic factor in multiple myelomaJerome Moreaux, Dirk Hose, Thierry Reme, et al.
NAR Genomics and Bioinformatics|September 25, 2024
Effective requesting method to detect fusion transcripts in chronic myelomonocytic leukemia RNA-seqFlorence Rufflé, Jérôme Reboul, Anthony Boureux, et al.
British Journal of Haematology|April 22, 2005
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remissionEric Jourdan, Françoise Rigal-Huguet, Gerald Marit, et al.
Pageof 9